The cited PMID is real, and it is a legitimate, high-quality source. It does not say what the post implies.

The review the post links to conducted a PRISMA-guided systematic review of peer-reviewed human and rodent intervention studies (January 2010 to October 2025) evaluating NAD-related compounds administered orally or parenterally, identifying 113 eligible studies: 33 human intervention studies (28 randomized; 5 nonrandomized) and 80 rodent studies .

Its findings split sharply by species. In rodent models, NAD⁺ augmentation was frequently associated with improvements in metabolic, mitochondrial, inflammatory, and functional outcomes, although effects varied across models and endpoints.

In humans, the picture is materially different: oral NR and NMN consistently demonstrated biochemical target engagement (circulating or cellular NAD-related metabolites) and were generally well tolerated over weeks to months; however, effects on functional, metabolic, vascular, and other healthspan-relevant outcomes were heterogeneous and often null or endpoint-specific.

That is the review's own conclusion. The supplement raises the biomarker. Whether it does anything useful for a human being is unresolved, with results frequently null.

Two independent meta-analyses reach compatible conclusions. The Nutrients meta-analysis found that no significant effects were observed on body weight, BMI, fasting glucose, HbA1c, lipid profiles, or systolic blood pressure; diastolic blood pressure decreased slightly, while HOMA-IR showed a non-significant downward trend . The authors themselves flag the one positive signal as fragile: although diastolic blood pressure showed a small statistically significant reduction, this finding should be interpreted as exploratory because blood pressure was not the primary endpoint in most included trials and multiple outcomes were analyzed .

The Critical Reviews in Food Science and Nutrition meta-analysis is blunter still, reporting no statistically significant changes in all outcome measures related to glucose metabolism, in sharp contrast with what has been found in animal models .

An earlier review of NMN human trials concluded that clear evidence for antiaging effects of NMN on the human body is still scarce , and that whether repletion of blood or tissue NAD⁺ through NMN or other precursor supplementation directly modifies the risk of disease, dysfunction, or toxicity in the general population is still to be established .

METHODOLOGY AND CONTEXT

Evidence hierarchy position: The cited paper is a systematic review, which sits near the top of the evidence hierarchy. This matters: the post chose a strong source and then represented its weakest-supported implication.

Human evidence base scale: 33 human intervention studies against 80 rodent studies. The volume of enthusiasm in the field is disproportionately rodent-derived.

"Target engagement" is a pharmacology term, not an outcome term. It means the compound reached its intended biochemical target. It is a necessary precondition for benefit, not evidence of benefit. The post converts this into functional claims about mitochondrial health, cellular resilience, and repair.

Duration: Human trials ran weeks to months . No human trial evidence exists at the timescale a lifespan or "cell lifespan" claim would require.

Known limitations of the human literature: current clinical evidence remains limited by small sample sizes, heterogeneous study populations, and short intervention durations .

Declared competing interest in the cited review: one author is an owner of a management services organization providing administrative services to an aesthetics clinic, which does not offer NAD⁺ infusions or supplementation; the authors declare no other competing interests . This is disclosed and appears low-risk, and the review's conclusions are notably conservative.

Regulatory context: NMN's legal status is recent and contested, not settled science. In two letters dated September 29, 2025, the FDA confirmed that NMN is not excluded from the definition of a dietary supplement, reversing its previous position that had excluded NMN products from the market.

The reversal centered on the "race to market" provision, with the agency concluding there was enough evidence that NMN was marketed as a dietary supplement before it was authorized for drug investigation. This is a procedural determination about market eligibility. It is not an efficacy finding, and readers frequently misread such news as validation.

Commercial context: The post pairs a scientific citation with "I've linked all of them in my bio" and #viral. This is affiliate or product-driven content. The citation functions as credibility decoration rather than as evidence the author is representing faithfully.